HOLOGIC INC Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 35 rows in 2024. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-12-11: Reporting owner Madaus Martin D; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction Holding.
- 2024-12-04: Reporting owner Mitchell Essex D; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2024-12-04: Reporting owner Mitchell Essex D; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2024-12-04: Reporting owner Mitchell Essex D; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-12-11 holding as of filing | Madaus Martin D Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | 1,016 owned after | $75.79 exercise price | 2024-12-11 | |
| 2024-12-04 | Mitchell Essex D Officer (Chief Operating Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,956 0 owned after | $40.97 exercise price | 2024-12-06 | |
| 2024-12-04 | Mitchell Essex D Officer (Chief Operating Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,526 0 owned after | $45.61 exercise price | 2024-12-06 | |
| 2024-12-04 | Mitchell Essex D Officer (Chief Operating Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,505 0 owned after | $68.35 exercise price | 2024-12-06 | |
| 2024-12-04 | Mitchell Essex D Officer (Chief Operating Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,915 2,972 owned after | $71.13 exercise price | 2024-12-06 | |
| 2024-11-11 | MACMILLAN STEPHEN P Director, Officer (Chairman, President and CEO) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +117,801 117,801 owned after | $79.39 exercise price | 2024-11-12 | |
| 2024-11-11 | Verstreken Jan Officer (Group President, International) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,698 18,698 owned after | $79.39 exercise price | 2024-11-12 | |
| 2024-11-11 | Schnittker Brandon Officer (Div. President, GYN Surgical) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,414 8,414 owned after | $79.39 exercise price | 2024-11-12 | |
| 2024-11-11 | Schneiders Jennifer M Officer (President, Diag. Solutions) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,698 18,698 owned after | $79.39 exercise price | 2024-11-12 | |
| 2024-11-11 | Oberton Karleen Marie Officer (Chief Financial Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,047 28,047 owned after | $79.39 exercise price | 2024-11-12 | |
| 2024-11-11 | Mitchell Essex D Officer (Chief Operating Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,722 32,722 owned after | $79.39 exercise price | 2024-11-12 | |
| 2024-11-11 | Griffin John M. Officer (General Counsel) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,698 18,698 owned after | $79.39 exercise price | 2024-11-12 | |
| 2024-11-11 | COHN BENJAMIN JORDAN Officer (Principal Accounting Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,505 3,505 owned after | $79.39 exercise price | 2024-11-12 | |
| 2024-11-11 | Anderson Erik S Officer (Div. Pres., Breast & Skeletal) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +14,023 14,023 owned after | $79.39 exercise price | 2024-11-12 | |
| 2024-08-29 | Oberton Karleen Marie Officer (Chief Financial Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −26,080 0 owned after | $40.97 exercise price | 2024-09-03 | |
| 2024-08-29 | Oberton Karleen Marie Officer (Chief Financial Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,725 0 owned after | $40.85 exercise price | 2024-09-03 | |
| 2024-07-30 | MACMILLAN STEPHEN P Director, Officer (Chairman, President and CEO) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −44,039 0 owned after | $26.21 exercise price | 2024-08-01 | |
| 2024-07-17 | MACMILLAN STEPHEN P Director, Officer (Chairman, President and CEO) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,672 44,039 owned after | $26.21 exercise price | 2024-07-19 | |
| 2024-07-17 | Stamoulis Christiana Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,039 0 owned after | $26.74 exercise price | 2024-07-19 | |
| 2024-03-14 | GARRETT SCOTT T Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,039 0 owned after | $26.74 exercise price | 2024-03-15 | |
| 2024-03-14 | GARRETT SCOTT T Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,402 0 owned after | $36.04 exercise price | 2024-03-15 | |
| 2024-03-08 | CRAWFORD SALLY Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,039 0 owned after | $26.74 exercise price | 2024-03-11 | |
| 2024-03-07 | Dockendorff Charles J Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,536 4,536 owned after | $76.32 exercise price | 2024-03-11 | |
| 2024-03-07 | CRAWFORD SALLY Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,536 4,536 owned after | $76.32 exercise price | 2024-03-11 | |
| 2024-03-07 | Wendell Amy McBride Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,536 4,536 owned after | $76.32 exercise price | 2024-03-11 | |
| 2024-03-07 | Stewart Stacey D. Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,536 4,536 owned after | $76.32 exercise price | 2024-03-11 | |
| 2024-03-07 | Stamoulis Christiana Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,536 4,536 owned after | $76.32 exercise price | 2024-03-11 | |
| 2024-03-07 | Mohtashami Nanaz Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,536 4,536 owned after | $76.32 exercise price | 2024-03-11 | |
| 2024-03-07 | HANTSON LUDWIG Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,536 4,536 owned after | $76.32 exercise price | 2024-03-11 | |
| 2024-03-07 | GARRETT SCOTT T Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,536 4,536 owned after | $76.32 exercise price | 2024-03-11 | |
| 2024-01-10 holding as of filing | Schnittker Brandon Officer (Div. President, GYN Surgical) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $74.65 exercise price | 2024-01-10 | ||
| 2024-01-10 holding as of filing | Schnittker Brandon Officer (Div. President, GYN Surgical) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $74.35 exercise price | 2024-01-10 | ||
| 2024-01-10 holding as of filing | Schnittker Brandon Officer (Div. President, GYN Surgical) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $71.94 exercise price | 2024-01-10 | ||
| 2024-01-10 holding as of filing | Schnittker Brandon Officer (Div. President, GYN Surgical) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $71.03 exercise price | 2024-01-10 | ||
| 2024-01-02 | Dockendorff Charles J Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,551 0 owned after | $38.44 exercise price | 2024-01-04 |